Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties
Top Cited Papers
- 24 August 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 110 (8), 904-910
- https://doi.org/10.1161/01.cir.0000139333.83620.5d
Abstract
Background— Ranolazine is a novel antianginal agent capable of producing antiischemic effects at plasma concentrations of 2 to 6 μmol/L without reducing heart rate or blood pressure. The present study examines its electrophysiological effects in isolated canine ventricular myocytes, tissues, and arterially perfused left ventricular wedge preparations. Methods and Results— Transmembrane action potentials (APs) from epicardial and midmyocardial (M) regions and a pseudo-ECG were recorded simultaneously from wedge preparations. APs were also recorded from epicardial and M tissues. Whole-cell currents were recorded from epicardial and M myocytes. Ranolazine inhibited I Kr (IC 50 =11.5 μmol/L), late I Na , late I Ca , peak I Ca , and I Na-Ca (IC 50 =5.9, 50, 296, and 91 μmol/L, respectively) and I Ks (17% at 30 μmol/L), but caused little or no inhibition of I to or I K1 . In tissues and wedge preparations, ranolazine produced a concentration-dependent prolongation of AP duration of epicardial but abbreviation of that of M cells, leading to reduction or no change in transmural dispersion of repolarization (TDR). At [K + ] o =4 mmol/L, 10 μmol/L ranolazine prolonged QT interval by 20 ms but did not increase TDR. Extrasystolic activity and spontaneous torsade de pointes (TdP) were never observed, and stimulation-induced TdP could not be induced at any concentration of ranolazine, either in normal or low [K + ] o . Ranolazine (5 to 20 μmol/L) suppressed early afterdepolarizations (EADs) and reduced the increase in TDR induced by the selective I Kr blocker d -sotalol. Conclusions— Ranolazine produces ion channel effects similar to those observed after chronic amiodarone (reduced I Kr , I Ks , late I Na , and I Ca ). The actions of ranolazine to suppress EADs and reduce TDR suggest that, in addition to its antianginal actions, the drug may possess antiarrhythmic activity.This publication has 28 references indexed in Scilit:
- Assessing predictors of drug-induced torsade de pointesTrends in Pharmacological Sciences, 2003
- Transmural Electrophysiological Heterogeneities Underlying Arrhythmogenesis in Heart FailureCirculation Research, 2003
- Cisapride-Induced Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial StimulationCirculation, 2003
- Electrophysiological Mechanism of Enhanced Susceptibility of Hypertrophied Heart to Acquired Torsade de Pointes ArrhythmiasCirculation, 2002
- Chronic Amiodarone Evokes No Torsade de Pointes Arrhythmias Despite QT Lengthening in an Animal Model of Acquired Long-QT SyndromeCirculation, 2001
- The QT intervalProgress in Cardiovascular Diseases, 2001
- The M Cell:Journal of Cardiovascular Electrophysiology, 1999
- A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agentsThe American Journal of Cardiology, 1999
- Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour holter electrocardiographyJournal of the American College of Cardiology, 1996
- Effects of amiodarone, sematilide, and sotalol on QT dispersionThe American Journal of Cardiology, 1994